Your browser doesn't support javascript.
loading
Management of sorafenib-related adverse events: a clinician's perspective.
Brose, Marcia S; Frenette, Catherine T; Keefe, Stephen M; Stein, Stacey M.
Afiliação
  • Brose MS; Assistant Professor, Director of the Thyroid Cancer Therapeutics Program, Department of Otorhinolaryngology: Head and Neck Surgery, and the Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Frenette CT; Medical Director of Liver Transplantation, Center for Organ and Cell Transplantation, Scripps Clinic, San Diego, CA. Electronic address: Frenette.Catherine@scrippshealth.org.
  • Keefe SM; Assistant Professor, Division of Hematology/Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.
  • Stein SM; Assistant Professor of Medicine, Department of Medical Oncology, Yale School of Medicine, New Haven, CT.
Semin Oncol ; 41 Suppl 2: S1-S16, 2014 Feb.
Article em En | MEDLINE | ID: mdl-24576654
Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable hepatocellular carcinoma (HCC) and advanced renal cell carcinoma (RCC). It is being evaluated in phase II and III clinical trials, which include treatment as a single agent (locally advanced/metastatic radioactive iodine-refractory differentiated thyroid cancer [DTC]), as part of multimodality care (HCC), and in combination with chemotherapeutic agents (metastatic breast cancer). Sorafenib-related adverse events (AEs) that commonly occur across these tumor types include hand-foot skin reaction (HSFR), rash, upper and lower gastrointestinal (GI) distress (ie, diarrhea), fatigue, and hypertension. These commonly range from grade 1 to 3, per the Common Terminology Criteria for Adverse Events (CTCAE), and often occur early in treatment. The goal for the management of these AEs is to prevent, treat, and/or minimize their effects, thereby enabling patients to remain on treatment and improve their quality of life. Proactive management, along with ongoing patient education (before and during sorafenib treatment), can help to effectively manage symptoms, often without the need for sorafenib dose modification or drug holidays. Effective management techniques for common sorafenib-related AEs, as well other important disease sequelae not directly related to treatment, are presented. Recommendations and observations are based on physician/author experience and recommendations from published literature.
Assuntos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Niacinamida / Síndrome Mão-Pé / Hipertensão / Antineoplásicos Tipo de estudo: Guideline Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Semin Oncol Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Compostos de Fenilureia / Niacinamida / Síndrome Mão-Pé / Hipertensão / Antineoplásicos Tipo de estudo: Guideline Aspecto: Patient_preference Limite: Humans Idioma: En Revista: Semin Oncol Ano de publicação: 2014 Tipo de documento: Article País de publicação: Estados Unidos